Starlink Internet Remains Active in Iran Despite Nationwide Blackout 
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition 
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny 
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
NYC Nurses Strike Shuts Down 10 Private Hospitals as 15,000 Demand Safer Staffing and Benefits 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges 
WALTHAM, Mass., March 28, 2017 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that management will present at the 16th Annual Needham Healthcare Conference on Tuesday, April 4, 2017 at 4:20 p.m. ET.
A live audio webcast will be accessible through the Investors section of the company’s website at www.amagpharma.com, and will be archived for 30 days.
About AMAG
AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Our currently marketed products support the health of patients in the areas of women’s health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine. For additional company information, please visit www.amagpharma.com.
AMAG Pharmaceuticals® is a registered trademark of AMAG Pharmaceuticals, Inc. and CBR® is a registered trademark of CBR Systems, Inc.
AMAG Pharmaceuticals Contact: Christi Waarich Associate Director, Investor Relations 617-498-7638
